Drug discovery initiative TaNeDS opens for applications
1 October 2015 | By Victoria White
The TaNeDS programme provides close partnership between successful applicants and scientists in Daiichi Sankyo to tackle unmet medical needs...
List view / Grid view
News
Cancer stopped in its tracks by reprogrammed fibroblasts
1 October 2015 | By Victoria White
If further studies show this route can benefit patients, it could help crack one of the toughest challenges in cancer research – how to stop tumours spreading...
FDA grants orphan drug designation to BLU-554
30 September 2015 | By Victoria White
BLU-554, an exquisitely selective inhibitor of fibroblast growth factor receptor 4 (FGFR4), is currently being evaluated in a Phase 1 clinical trial in patients with advanced hepatocellular carcinoma...
Aspen Park acquires rights to castration resistant prostate cancer drug
30 September 2015 | By Victoria White
APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer...
UbiVac and Janssen to develop vaccine to intercept oral cancer
30 September 2015 | By Victoria White
Development of an immunotherapy that induced broad anti-cancer immunity and inhibited oral leukoplakia from transforming into oral cancer would represent a paradigm shift for treating this disease...
CARsgen partners with Shanghai Cancer Institute to advance CAR-T therapies
30 September 2015 | By Victoria White
The partners will work together to identify and develop novel CAR-T candidates as well as next-generation CAR-T technologies...
Innovate UK awards Congenica £300,000
29 September 2015 | By Victoria White
Congenica’s platform Sapientia has been developed to analyse and interpret whole genome data. With this grant Congenica will be able to extend its capability to include other types of -omics data...
New company LA Cell to focus on cell-penetrating antibody therapies
29 September 2015 | By Victoria White
LA Cell has exclusively licensed technology that enables modified monoclonal antibodies to penetrate into cells and target "undruggable" disease-causing molecules...
Apitope raises €12 million in Series B funding
29 September 2015 | By Victoria White
The funds will enable Apitope to progress the clinical development of its innovative pipeline which includes therapies for Factor VIII intolerance in Haemophilia A patients...
PL-3994 reduces cardiac hypertrophy in heart failure study
29 September 2015 | By Victoria White
Preclinical data showed that treatment with PL-3994 significantly reduced cardiac hypertrophy and pro-fibrotic and inflammatory gene activation...
LDC and Infinity to work together on oncology drug discovery
29 September 2015 | By Victoria White
LDC and Infinity will work together to select high-potential cancer drug discovery projects from the LDC’s portfolio and its broad academic network...
New CRISPR system could change the scientific landscape
28 September 2015 | By Victoria White
The newly described Cpf1 system differs in several important ways from Cas9, with significant implications for research and therapeutics...
Heptares gets grant to develop cocaine addiction treatment
28 September 2015 | By Victoria White
The $5.5 million grant will support a three-year research project aimed at developing a selective antagonist for the human Orexin-1 receptor...
H7N9 influenza vaccine failure due to “immune camouflage”
28 September 2015 | By Victoria White
H7N9 candidate vaccines have failed to elicit a strong immune response necessary to protect from infection. A study has revealed that it may be due to immune camouflage...
Protectimmun and ICL team up for preclinical asthma research
28 September 2015 | By Victoria White
The research agreement, facilitated by Johnson & Johnson Innovation, will fund preclinical research with a drug candidate in a proof-of-concept disease model of allergic asthma...